



## miRagen Therapeutics to Present at two Investor Conferences in November 2018

October 29, 2018

BOULDER, Colo., Oct. 29, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that William S. Marshall, Ph.D., President and Chief Executive Officer, is scheduled to participate in two investor conferences in November 2018.

### Jefferies London Healthcare Conference

Date: Thursday, November 15<sup>th</sup>

Time: 8:00 a.m. GMT

Location: London, UK

Webcast: <http://wsw.com/webcast/jeff115/mgen>

### Evercore ISI HealthconX Conference

Date: Tuesday, November 27<sup>th</sup>

Time: 2:20 p.m. EST

Location: Boston, MA

Webcast: <http://wsw.com/webcast/evercore2/mgen>

Live webcasts of both presentations can also be accessed by visiting the "Investors & Media" section of the Company's web site at [www.miragen.com](http://www.miragen.com). A replay of the webcast will be available for 90 days after each event.

### About miRagen Therapeutics, Inc.

miRagen Therapeutics, Inc. is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. miRagen has three clinical stage product candidates, cobomarsen (MRG-106), remlarsen (MRG-201), and MRG-110. miRagen's clinical product candidate for the treatment of certain cancers, cobomarsen, is an inhibitor of microRNA-155, which is found at abnormally high levels in malignant cells of several blood cancers, as well as certain cells involved in inflammation. miRagen's clinical product candidate for the treatment of pathological fibrosis, remlarsen, is a replacement for microRNA-29, which is found at abnormally low levels in a number of pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, pulmonary and ocular fibrosis, as well as systemic sclerosis. MRG-110, an inhibitor of microRNA-92, is being developed under a license and collaboration agreement with Servier for the treatment of heart failure and other ischemic disease. In addition to these programs, miRagen is developing a pipeline of preclinical product candidates. The goal of miRagen's translational medicine strategy is to progress rapidly to first-in-human studies once it has established the pharmacokinetics, pharmacodynamic, safety and manufacturability of the product candidate in preclinical studies. For more information, please visit [www.miragen.com](http://www.miragen.com).

For information on clinical trials please visit [www.clinicaltrials.gov](http://www.clinicaltrials.gov).

### Investor/Media Contact:

Adam Levy

Chief Business Officer

(720) 407-4595

[alevy@miragen.com](mailto:alevy@miragen.com)



Source: Miragen Therapeutics, Inc.